Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03645993 · ClinicalTrials.gov registry record
Early Onset Alzheimer's Disease Genomic Study
A clinical trial, sponsored by Baylor Research Institute.
- Completed
- Registry status
- 26
- Enrollment target
NCT03645993 is a clinical trial that has completed, run by Baylor Research Institute. The registered enrollment target is 26 participants.
The verdict
NCT03645993 has completed, sponsored by Baylor Research Institute.
- COMPLETED
- Registry status
- 26 participants
- Enrollment target
Study Summary
The purpose of this study is to collect samples from patients with Early-Onset Alzheimer's disease (AD) and their immediate family members for molecular analysis. Samples will be studied in order to understand how molecular changes in the body are related to the development of the disease. Researchers will study your DNA and RNA in order to help doctors diagnose, treat, and monitor people at risk of developing Early-Onset AD in the future.
Interventions
- GENETIC Genetic Testing
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2017-06-16 |
| Est. Completion | 2024-04-24 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03645993
The ClinicalTrials.gov registry entry for NCT03645993 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Baylor Research Institute, which has 180 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Genetic Testing is the first listed.
NCT03645993 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03645993 about?
NCT03645993 is a clinical study titled "Early Onset Alzheimer's Disease Genomic Study". The purpose of this study is to collect samples from patients with Early-Onset Alzheimer's disease (AD) and their immediate family members for molecular analysis. Samples will be studied in order to understand how molecular changes in the body are related to the development of the disease. Researche...
What is the current status of trial NCT03645993?
This trial is currently completed. The enrollment target is 26 participants. The study started on 2017-06-16. Estimated completion is 2024-04-24.
What interventions are being tested in trial NCT03645993?
The interventions under investigation include: Genetic Testing (GENETIC).
Who is sponsoring clinical trial NCT03645993?
This trial is sponsored by Baylor Research Institute, which has 180 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.